

List of Figure

FIGURE 1 1 Development of cancer.....4

FIGURE 1 2 Types of liposomes employed for drug delivery 10

FIGURE 1 3 Passive accumulation of liposomes at tumour through leaky tumour endothelium 13

FIGURE 1 4 Schematic representation (a) coupling reaction between functionalized PEG chain and cyclic RGD peptide (b) targeted liposome delivery system 14

FIGURE 1 5 A multifunctional liposome with multiple targets and triggered release mechanisms..... 32

FIGURE 1 6 Chemical structure of deoxycytidine and the antimetabolite gemcitabine 39

List of Table

TABLE 1 1 Some chemotherapeutic agents used in the treatment of cancer.....6

TABLE 1 2 List of FDA approved liposomal agents8

List of Tables

TABLE 2 1 Experimental conditions for Gemcitabine HCl by UV method were as below. 57

TABLE 2 2 Experimental conditions for Gemcitabine HCl by HPLC method were as below. 59

TABLE 2 3. Absorbance and Calibration Data of Gemcitabine HCl for Linearity 61

TABLE 2 4. Absorbance and Calibration Data of Gemcitabine HCl (after 24hr) for Stability 62

TABLE 2 5. Intraday and Interday Precision Analysis of UV Method 63

TABLE 2 6. Accuracy of the UV Method..... 64

TABLE 2 7. Specificity and Interference Study of Formulation Component 64

TABLE 2 8. Peak Area and Calibration Data of Gemcitabine HCl for Linearity 66

TABLE 2 9. Intraday and Interday Precision Analysis of HPLC Method..... 67

TABLE 2 10. Accuracy of the HPLC Method..... 67

List of Figure

FIGURE 2 1. UV Absorption Spectrum of Gemcitabine HCl in Distilled Water..... 60

FIGURE 2 2. UV Absorption Spectrum of Gemcitabine HCl in Phosphate Buffer pH 7.4 60

FIGURE 2 3. UV Absorption Spectrum of Gemcitabine HCl in Methanol..... 60

FIGURE 2 4. Calibration Curve of Gemcitabine HCl in Different Solvents 61

FIGURE 2 5. Calibration curve of Gemcitabine HCl in Different Solvents after 24hr for stability study..... 62

FIGURE 2 6. Specificity and Interference Study Graph between Gemcitabine HCl and Excipients 65

FIGURE 2 7. Typical Chromatogram of Gemcitabine HCl by HPLC..... 65

FIGURE 2 8. Calibration Curve of Gemcitabine HCl by HPLC..... 66

List of Table

Table 3.1 Various Liposomal Formulations with Their Composition	78
Table 3.2 Independent variables and their corresponding levels	79
Table 3.3 Thermal Cycling for Lyophilization of formulation	80
Table 3.4 Selection of method for preparation of liposomes.....	84
Table 3.5 Selection of Process Parameters for Liposomes Preparation	86
Table 3.6 Selection of the lipids.....	87
Table 3.7 3 ³ Full factorial design consisting of experiments for the study of three experimental factors in coded and actual levels with experimental results	90
Table 3.8 Optimization of drug loading level	91
Table 3.9 Effect of cholesterol concentration on % drug loading and mean particle size	92
Table 3.10 Effect of DSPE-mPEG ₂₀₀₀ and DSPE-mPEG ₂₀₀₀ -RGD concentration on % drug content and mean particle size	93
Table 3.11 Optimization of Lyophilization.....	94
Table 3.12 Drug Content of various formulation.....	95
Table 3.13 Mean particle size and zeta potential various liposomal formulations	96
Table 3.14 Residual Water Content of Various Lyophilized Products	97

List of Figure

Figure 3.1 Particle size reports of the RGD-grated optimized liposomes.....	96
Figure 3.2 Zeta potential reports of the RGD-grated optimized liposomes.....	96
Figure 3 3 CryoTEM image of RGD grafted optimized liposomes.	97

List of Table

TABLE 4 1. Viability of A549 Cells on Exposure to Liposomes	111
TABLE 4 2. Cell-Line Treatment Parameters for Flow-Cytometry	113
TABLE 4 3. Cell-Line Treatment Parameters for Confocal Microscopy	114
TABLE 4 4 Uptake of Liposomes in A549 Cells.....	116
TABLE 4 5. Chemosensitization of Gemcitabine HCl in A549 Cells	124
TABLE 4 6. Chemosensitization of Gemcitabine HCl in H1299 Cells	126
TABLE 4 7. IC ₅₀ values of Various Formulations with or without siRNA	127
TABLE 4 8. Change in IC ₅₀ of Gemcitabine HCl after Chemosensitization by RGD-DDHC Liposomes(2%).....	128
TABLE 4 9. Change in IC ₅₀ of Gemcitabine HCl After Chemosensitization by RGD-CPE Liposomes(2%).....	128
TABLE 4 10. Change in IC ₅₀ of Gemcitabine HCl After Chemosensitization by Lipofectamine 2000.....	129
TABLE 4 11. Comparison of Change in IC ₅₀ Value of Various Formulation.....	129
TABLE 4 12. Haemolysis by Liposomes	133
TABLE 4 13. Influence of sodium chloride concentration on mean particle size of liposomes.....	136

List OF Figure

FIGURE 4 1. Cell Counting Using Haemocytometer	107
FIGURE 4 2. Haemocytometer diagram for cell counting.....	108
FIGURE 4 3. Cytotoxicity of Different Liposomes in A549 Cell-line.....	111
FIGURE 4 4 Uptake of Liposomes in A549 Cells	116
FIGURE 4 5. Quantification of Mean Fluorescence Intensity in A549 Cells.....	117
FIGURE 4 6. Uptake of Liposomes in A549 Cells	117
FIGURE 4 7. Cell Uptake in A549 Cell Line	118
FIGURE 4 8. Live uptake of CLs and RGD grafted liposomes in A549 cells	119
FIGURE 4 9. 3D Z-stack image for CLs liposomes uptake	120
FIGURE 4 10. 3D Z-stack Image for RGD-Grafted Liposomes Uptake.....	120
FIGURE 4 11. Cell Growth Inhibition in H1299 Cells	121
FIGURE 4 12. . Chemosensitization of Gemcitabine in A549 Cells by siRNA	125
FIGURE 4 13. Chemosensitization of Gemcitabine in H1299 Cells by siRNA.....	127
FIGURE 4 14. <i>In vitro</i> Release of GEM from Liposomes	131
FIGURE 4 15. Haemolytic Potential of Liposomes.....	134
FIGURE 4 16. Electrolyte Induced Flocculation of Liposomes	136

CHAPTER:5 IN VIVO TOXICITY STUDY

List of Table

TABLE 5 1. Sighting Study: Dosing protocol	144
TABLE 5 2 Results of Sighting Study	145
TABLE 5 3 MTD Study: Dosing Protocol	145
TABLE 5 4 Results for MTD study	146

CHAPTER: 6 STABILITY STUDIES

Table of content

Table 6 1Stability Testing Data of RGD-grafted optimized Liposomes (3%).....	150
--	-----